Supernus highlights Onepco rebound, CNS portfolio growth after Q1 earnings call

Supernus Pharmaceuticals (SUPN) said first-quarter revenue growth was driven by stronger demand for key growth products and a rebound in new patient starts for Onepco, prompting a positive market reaction after its earnings call. CEO Jack Khattar said Onepco prescription activity in March exceeded levels seen before supply constraints. Management also cited broader prescriber adoption and patient reach for Zirzuve and Kelli as contributors to the quarter’s performance. Investors are watching the approval timeline and onboarding of a second Onapro supplier, prescription trends and patient conversion for Onepco and Kelli, and clinical milestones for SPN-820 and SPN-817. Supernus shares traded at $49.42 after the call, little changed from $49.19 before earnings.